According to the latest status from July 2024, Tasly Pharmaceutical Group Co paid a total of 0.33 CNY per share in dividends within the last 12 months. With the current Tasly Pharmaceutical Group Co price of 12.58 CNY, this corresponds to a dividend yield of 2.62 %. A dividend is paid times per year.
| 2.62 % Dividend Yield | = |
|
A dividend is paid times per year. Last year, the payout months were and June.
| Paydate | Dividend |
|---|---|
| 6/29/2024 | 0.33 |
| 6/22/2023 | 0.33 |
| 7/20/2022 | 0.33 |
| 7/24/2021 | 0.33 |
| 7/12/2020 | 0.33 |
| 7/13/2019 | 0.3 |
| 7/5/2018 | 0.29 |
| 7/15/2017 | 0.56 |
| 6/25/2016 | 0.42 |
| 6/21/2015 | 0.39 |
| 7/19/2014 | 0.35 |
| 6/22/2013 | 0.1 |
| 7/7/2012 | 0.7 |
| 6/24/2011 | 0.6 |
| 7/7/2010 | 0.4 |
| 5/13/2009 | 0.4 |
| 5/30/2008 | 0.3 |
| 6/30/2007 | 0.18 |
| 5/13/2006 | 0.3 |
| 6/19/2005 | 0.3 |
3 years
5 years
10 years
Max
The dividend per year chart for Tasly Pharmaceutical Group Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.
A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Tasly Pharmaceutical Group Co’s potential for long-term investment and income generation through dividends.
Incorporate the dividend data in evaluating Tasly Pharmaceutical Group Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.
| Date | Tasly Pharmaceutical Group Co Dividend |
|---|---|
| 2026e | 0.33 undefined |
| 2025e | 0.33 undefined |
| 2024e | 0.33 undefined |
| 2023 | 0.33 undefined |
| 2022 | 0.33 undefined |
| 2021 | 0.33 undefined |
| 2020 | 0.33 undefined |
| 2019 | 0.3 undefined |
| 2018 | 0.29 undefined |
| 2017 | 0.4 undefined |
| 2016 | 0.3 undefined |
| 2015 | 0.28 undefined |
| 2014 | 0.25 undefined |
| 2013 | 0.07 undefined |
| 2012 | 0.25 undefined |
| 2011 | 0.21 undefined |
| 2010 | 0.14 undefined |
| 2009 | 0.14 undefined |
| 2008 | 0.11 undefined |
| 2007 | 0.06 undefined |
| 2006 | 0.07 undefined |
| 2005 | 0.07 undefined |
| 2004 | 0.07 undefined |
| Dividend | Dividend (Estimate) | |
|---|---|---|
| 2004 | 0.07 CNY | 0 CNY |
| 2005 | 0.07 CNY | 0 CNY |
| 2006 | 0.07 CNY | 0 CNY |
| 2007 | 0.06 CNY | 0 CNY |
| 2008 | 0.11 CNY | 0 CNY |
| 2009 | 0.14 CNY | 0 CNY |
| 2010 | 0.14 CNY | 0 CNY |
| 2011 | 0.21 CNY | 0 CNY |
| 2012 | 0.25 CNY | 0 CNY |
| 2013 | 0.07 CNY | 0 CNY |
| 2014 | 0.25 CNY | 0 CNY |
| 2015 | 0.28 CNY | 0 CNY |
| 2016 | 0.3 CNY | 0 CNY |
| 2017 | 0.4 CNY | 0 CNY |
| 2018 | 0.29 CNY | 0 CNY |
| 2019 | 0.3 CNY | 0 CNY |
| 2020 | 0.33 CNY | 0 CNY |
| 2021 | 0.33 CNY | 0 CNY |
| 2022 | 0.33 CNY | 0 CNY |
| 2023 | 0.33 CNY | 0 CNY |
| 2024e | 0 CNY | 0.33 CNY |
| 2025e | 0 CNY | 0.33 CNY |
| 2026e | 0 CNY | 0.33 CNY |
Tasly Pharmaceutical Group Co has been increasing the dividend for 1 years.
Over the past 10 years, Tasly Pharmaceutical Group Co has increased it by an annual 16.542 %.
Over a five-year period, the distribution increased by 2.924%.
Analysts expect a Dividend Cut of -0.705% for the current fiscal year.
3 years
5 years
10 years
Max
The yearly payout ratio for Tasly Pharmaceutical Group Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.
A lower payout ratio for Tasly Pharmaceutical Group Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.
Evaluate Tasly Pharmaceutical Group Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.
| Date | Tasly Pharmaceutical Group Co Payout ratio |
|---|---|
| 2026e | 33.79 % |
| 2025e | 30.6 % |
| 2024e | 33.95 % |
| 2023 | 36.82 % |
| 2022 | -183.33 % |
| 2021 | 21.02 % |
| 2020 | 44 % |
| 2019 | 45.45 % |
| 2018 | 28.01 % |
| 2017 | 43.96 % |
| 2016 | 38.46 % |
| 2015 | 28.43 % |
| 2014 | 26.32 % |
| 2013 | 9.39 % |
| 2012 | 42.37 % |
| 2011 | 51.02 % |
| 2010 | 43.3 % |
| 2009 | 62.13 % |
| 2008 | 56.37 % |
| 2007 | 44.71 % |
| 2006 | 41.88 % |
| 2005 | 44.67 % |
| 2004 | 51.54 % |
| Payout ratio | |
|---|---|
| 2004 | 51.54 % |
| 2005 | 44.67 % |
| 2006 | 41.88 % |
| 2007 | 44.71 % |
| 2008 | 56.37 % |
| 2009 | 62.13 % |
| 2010 | 43.3 % |
| 2011 | 51.02 % |
| 2012 | 42.37 % |
| 2013 | 9.39 % |
| 2014 | 26.32 % |
| 2015 | 28.43 % |
| 2016 | 38.46 % |
| 2017 | 43.96 % |
| 2018 | 28.01 % |
| 2019 | 45.45 % |
| 2020 | 44 % |
| 2021 | 21.02 % |
| 2022 | -183.33 % |
| 2023 | 36.82 % |
| 2024e | 33.95 % |
| 2025e | 30.6 % |
| 2026e | 33.79 % |
Tasly Pharmaceutical Group Co’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.
Examining Tasly Pharmaceutical Group Co's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.
Tasly Pharmaceutical Group Co's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.
Changes in Tasly Pharmaceutical Group Co’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.
Over the past 12 months, Tasly Pharmaceutical Group Co paid a dividend of 0.33 CNY . This corresponds to a dividend yield of about 2.62 %. For the coming 12 months, Tasly Pharmaceutical Group Co is expected to pay a dividend of 0.33 CNY.
The current dividend yield of Tasly Pharmaceutical Group Co is 2.62 %.
Tasly Pharmaceutical Group Co pays a quarterly dividend. This is distributed in the months of July, July, June, June.
Tasly Pharmaceutical Group Co paid dividends every year for the past 23 years.
For the upcoming 12 months, dividends amounting to 0.33 CNY are expected. This corresponds to a dividend yield of 2.58 %.
Tasly Pharmaceutical Group Co is assigned to the 'Health' sector.
To receive the latest dividend of Tasly Pharmaceutical Group Co from 5/29/2024 amounting to 0.33 CNY, you needed to have the stock in your portfolio before the ex-date on 5/29/2024.
The last dividend was paid out on 5/29/2024.
In the year 2023, Tasly Pharmaceutical Group Co distributed 0.33 CNY as dividends.
The dividends of Tasly Pharmaceutical Group Co are distributed in CNY.
Our stock analysis for Tasly Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tasly Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.